Table 1 Overall profile 1 (P1) in Caucasian and Chinese.

From: Antihypertensive treatment guided by genetics: PEARL-HT, the randomized proof-of-concept trial comparing rostafuroxin with losartan

Caucasian

Chinese

ADD1 rs4961 GT + TT & ADD3 rs3731566 GG

ADD1 rs4961 GT + TT & ADD3 rs2501574 TT

ABCB1/MDR1 rs1045642 TT & HSD3B1 rs10923835 AT + TT

ABCB1/MDR1 rs1045642 TT & HSD3B1 rs117585927 CG + CC

LSSrs2254524 CA + AA & ABCB1/MDR1 rs1045642 CC

LSSrs2254524 CA + AA & ABCB1/MDR1 rs1045642 CC

LSSrs2254524 AA & ADD1 rs4961 GT + TT

LSS rs2254524 AA & ADD1 rs4961 GT + TT

rs16893522 = AA

rs16893522 = AA

rs2345088 = TT

rs2345088 = TT

rs2461911 = AA

rs2461911 = AA

rs16877182 = CT

rs16877182 = CT

rs12513375 = GG

rs12513375 = GG

HSD3B1 rs947130 GG & NEDD4L rs4245268 CC

HSD3B1 rs947130 GG & NEDD4L rs4245268 CC

ABCB1/MDR1 rs1045642 CC & AGTR1 rs2131127 CC

ABCB1/MDR1 rs1045642 CC & AGTR1 rs2131127 CC

ADD2 rs4984 CC & rs10502933 CT

ADD2 rs12470211 AG + GG & rs10502933 CT

LSS rs2254524 AA & WNK1 rs880054 AG + GG

LSS rs2254524 AA & WNK1 rs880054 AG + GG

  1. Genotype combinations in P1 and P2 (in bold) both in Caucasian and in Chinese. Genotype variations specific to Chinese are in italics and underlined, as explained in the online-only Supplementary Data. P1 was composed by adding to the gene variants included in the P2, the variants detected by post-hoc analysis of a previous OASIS-HT trial; P2, variants of genes encoding enzymes for endogenous ouabain (EO) synthesis (LSS and HSD3B1), EO transport (MDR1/ABCB1), adducin (ADD1 and ADD3); P3, variants of the LSS gene only (homozygous wild CC (major) and homozygous for the mutant genotype AA (minor)).
Back to article page